ACP
NUVB icon

Acuta Capital Partners’s Nuvation Bio NUVB Stock Holding History

Acuta Capital Partners’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-90,832
Closed -$69K – 48
2022
Q1 		$69K Hold
90,832
– – 0.03% 41
2021
Q4 		$172K Buy
+90,832
New +$835K 0.07% 36

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Acuta Capital Partners's NUVB Position: Q2 2022 in Review

Acuta Capital Partners sold out of Nuvation Bio (NUVB) in Q2 2022, closing a stake of 90,832 shares — an estimated $69K sold.

Acuta Capital Partners first reported a position in NUVB in Q4 2021 and held it in 2 quarters. The position peaked at $172K in Q4 2021. 119 funds tracked by Wall St. Rank hold NUVB as of Q2 2022.

  • Acuta Capital Partners reported no remaining Nuvation Bio position as of Q2 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 90,832 Nuvation Bio shares in Q2 2022, an estimated $69K.
  • Acuta Capital Partners first reported a position in Nuvation Bio in Q4 2021 and held it in 2 quarters.
  • Acuta Capital Partners's Nuvation Bio position peaked at $172K in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.